Glenmark to set up first manufacturing facility in US

Glenmark Pharmaceuticals plans to set up its first manufacturing facility in the US at an estimated investment of over Rs 500 crore to cater to the North American market.
The proposed facility would house three units to produce oral solids, injectables and topicals and begin production by the end of the current fiscal.
"The US is a key strategic market for Glenmark and it is important for us to have a manufacturing base here to serve our growing business in the country," Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said in a statement.
The plan to set up a manufacturing facility in the US underlines the fast paced growth the company has witnessed in a short span of eight years in the US market, he added.

The company will first begin work on an oral solid unit and thereafter set up manufacturing units for injectables and topicals, the Mumbai-based firm said.
"Over the next five years, we will make significant investments in this proposed facility and set up three units which will produce oral solids, injectables and topicals," Saldanha said.

According to industry sources, the company plans to invest over Rs 500 crore on the facility.
With the setting up of a new facility in the US the company would further enhance its manufacturing footprint making it truly global in every sense of the term, he added.

The proposed facility at Monroe, North Carolina, will cater only to the US market and is the company's first manufacturing facility in North America adding to its list of 14 plants in four countries - India, Brazil, Argentina and Czech Republic.
The company, which operates in North America through its subsidiary Glenmark Generics Inc, has a fast growing business with a robust portfolio of over 90 products authorised for distribution in the US in niche segments like dermatology, hormones, controlled substances and oncology.
Glenmark has nearly 70 abbreviated new drug applications (ANDAs) pending for approval with the US Food and Drug Administration.

The company's scrip closed at Rs 564.55 on the BSE, up 1.36 per cent from its previous close.